Elan

113 results

Elan chief executive Kelly Martin, a former  Merrill Lynch banker, took the helm in 2003, drastically paring down the company and opting to focus on the development of multiple sclerosis drug Tysabri.  Photograph: Alan Betson

The sale of Elan to Perrigo marks the end of a rollercoaster ride for the Irish drugmaker, which has fended off three takeover bids by private equity (...)

The media and health care sectors have outperformed the market this year, with the STOXX Europe 600 media index up 17 percent and the STOXX Europe 600 health care index up 14.4 per cent, while the FTSEurofirst 300 is up 6.9 per cent. Photograph: Lucas Jackson/Reuters

European stocks rose today as a flurry of big mergers and acquisitions deals boosted sentiment and helped the market bounce back after a two-session d(...)

Elan put itself up for sale last month after rejecting three hostile bids from US investment firm Royalty Pharma.

US generic drugmaker Perrigo has agreed to buy fellow drug company Elan for $8.6 billion (€6.48 billion) in a deal that will hand it royalty rights fr(...)

Biotech group Elan reported quarterly income of $2.28 billion compared with a net loss of $28.5 million for the same period last year.The results incl(...)

Daybreak will act as an outsourced contractor, providing IT systems and backup to Elan and other biotech firmsbinary code

Up to 50 high-end engineering jobs will be created in Dublin through a new biotech systems management company headed up by Irish expats in Silicon Val(...)

The Elan Corporation pharmaceutical plant in Athlone. A US federal judge has been asked to dismiss two insider trading charges tied to sales of Elan’s US depositary receipts. Photograph: John Cogill/Bloomberg News

Former SAC Capital Advisors portfolio manager Mathew Martoma has urged a federal judge to dismiss two insider trading charges tied to his firm’s sales(...)

Suir Bridge. The Roche family, which founded the original National Toll Roads, still holds a 38 per cent share in the business with investment company One51 also a major shareholder.

NTR share buybackInvestment group NTR is examining the prospect of organising a share buyback or a special dividend to return €100 million to sharehol(...)

Pablo Legorreta, chief executive and founder of Royalty Pharma

Pablo Legorreta is down but not out. The man behind the high profile and often crabby campaign to acquire Ireland’s largest indigenous pharma group El(...)

Ryanair closed up 1.2 per cent 
at ¤7.06 
on a day in which it held an investor conference in London

Stock markets reacted badly yesterday to comments a day earlier from Federal Reserve chairman Ben Bernanke that the central bank may end bond purchase(...)

Shareholders may have bloodied the nose of Elan management with their rejection of its investment plans at Monday’s extraordinary general meeting but, in its most recent update, Royalty had secured acceptances of less than 8 per cent of Elan’s stock.

Royalty Pharma has only itself to blame for the failed hostile bid to acquire Irish biotech group Elan for up to $8 billion. The Dublin-headquartered (...)

  • « First
  • Prev
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • Last »